Plain-English translation of NCT06642272 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Diabetes Mellitus, Type 2 research guide →Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether empagliflozin and dapagliflozin work equally well for treating type 2 diabetes, heart failure, and chronic kidney disease. Both medications belong to the same family of drugs, but doctors want to know if one may be more effective than the other for these conditions. Your doctor will prescribe one of these medications as part of your regular care, and the study will track how well it works for you.
While both medications are already approved and prescribed for these conditions, doctors don't yet have clear evidence about whether one performs better than the other in real-world practice. This trial will help answer that question so patients and doctors can make better treatment choices.
You likely qualify if…
You likely don't qualify if…
You will take either empagliflozin or dapagliflozin as prescribed by your doctor—the assignment happens automatically through your hospital's electronic health records system. The study doesn't require extra visits beyond your normal doctor appointments; instead, researchers will monitor your health outcomes using your existing medical records. This is a large study following over 17,000 participants to see how the two medications perform in everyday clinical practice.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
Denmark